• HCV: DAA-induced clearance less likely with liver cancer

    Results of a 49-study meta-analysis.

  • Liver cancer: adjuvant TACE extends survival in low-risk patients

    Prior data focused on intermediate- to advanced-stage hepatocellular carcinoma.

  • CRC liver metastases: value of estimating conditional recurrence-free survival

    Risks change over time, and conditional RFS could provide a more accurate prognosis.

  • Treating HCV after liver cancer: timing matters

    HCC recurrence risk drops with DAA delay.

  • T2D doubles risk for severe LD

    Risk is even higher with male sex, high BMI, hypertension, and kidney disease markers.

  • HCC: analysis points to laparoscopic resection for small, single tumors

    Combines the effectiveness of open resection and the safety profile of RFA.

  • Small HCC: minimally invasive surgery or radiofrequency ablation?

    The study is the first meta-analysis comparing MIS and RFA in small HCC.

  • Childhood hepatoblastoma: minimal adjuvant chemotherapy yields good outcomes

    Reducing exposure in select patients could help prevent acute and long-term toxicities.

  • HCV cirrhosis: DAAs boost survival after successful HCC treatment

    Real-world data suggest effect driven by preserved hepatic function.

  • IVF: small increased risk for some rare childhood cancers

    1.7% of US births result from IVF.

  • CRC liver metastasis: when is R1 resection adequate?

    RAS status and NACT response should be considered.

  • HBV: daily aspirin therapy is tied to 29% lower HCC risk

    Daily low-dose aspirin demonstrates potential preventive effect.

  • Early HCC: resection best for elderly with tumors over 2 cm

    SEER analysis compares HR and RFA by age and tumor size.

  • HCC: AGA issues guidelines for DAA timing, surveillance

    Practice update from the American Gastroenterological Association.

  • GI cancer: time to do more in tackling unintentional weight loss?

    Interventions needed to increase awareness.

  • HBV: comorbid DM tied to higher odds of HCC, death

    An 11-year population-based propensity-matched analysis.

  • HCV: DAAs slash risk for early death, HCC in ANRS CO22

    Large cohort study shows 52% lower risk for death, 34% reduced risk for HCC.

  • Load more